Posts by: Alice Melão

News

The donor-derived, or allogeneic CAR T-cell therapy candidate UCARTCS1 has been administrated to the first patient in an ongoing Phase 1 trial for relapsed/refractory multiple myeloma. The study (NCT04142619), ... Read more

October 28, 2019

I-Mab Expands its Ongoing Myeloma Clinical Trials of MOR202 to China

News

I-Mab Biopharma is expanding to mainland China its ongoing clinical studies assessing MorphoSys‘ investigational antibody therapy MOR202 (TJ202) as treatment for people with multiple myeloma, the company announced. The ... Read more

October 21, 2019

Multiple Myeloma Patients Best Treated at Recognized Care Centers with High Volume, US Study Reports

News

Multiple myeloma patients treated in their community by local oncologists have poorer survival outcomes than those receiving care at centers that see large numbers of patients or are nationally ... Read more

October 9, 2019

Chinese Regulatory Agency Clears CT103A for Clinical Studies in Relapsed or Refractory Multiple Myeloma

News

IASO Biotherapeutics and Innovent Biologics are preparing the launch of a Phase 1b/2 clinical trial in China to evaluate the companies’ novel CAR T-cell product, CT103A, in people with ... Read more

September 25, 2019October 30, 2019

Carsgen’s CAR-T Cell Therapy Given Priority Designation in Europe for Multiple Myeloma

News

CT053, a novel cell-based therapy being developed by Carsgen Therapeutics, was given priority medicines (PRIME) status by the European Medicines Agency (EMA) as a potential treatment of relapsed or refractory ... Read more

June 14, 2019

Early Data Show Positive Activity of Iberdomide Against Heavily Treated MM

News

Interim data from an ongoing Phase 1/2 clinical trial show that Celgene’s investigational therapy iberdomide (CC-220), used in combination with dexamethasone, is safe and controlled disease in nearly 90% ... Read more

May 13, 2019May 13, 2019

Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing

News

A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide) plus dexamethasone, for the treatment of relapsed ... Read more

April 15, 2019

MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients

News

The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid leukemia and multiple myeloma, the company announced. The ... Read more

March 27, 2019

FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials

News

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the ... Read more

March 25, 2019

Phase 1/2 Trial of Tinostamustine Recruiting Patients with Myeloma, Other Blood Cancers

News

The expansion part of a Phase 1/2 clinical trial testing tinostamustine in relapsed or refractory blood cancers has begun treating the first patient. The trial (NCT02576496), conducted by Mundipharma EDO ... Read more

Posts by: Alice Melão

Alice Melão

First Multiple Myeloma Patient Dosed With CAR T-Cell Therapy UCARTCS1 in Phase 1 Trial

I-Mab Expands its Ongoing Myeloma Clinical Trials of MOR202 to China

Multiple Myeloma Patients Best Treated at Recognized Care Centers with High Volume, US Study Reports

Chinese Regulatory Agency Clears CT103A for Clinical Studies in Relapsed or Refractory Multiple Myeloma

Carsgen’s CAR-T Cell Therapy Given Priority Designation in Europe for Multiple Myeloma

Early Data Show Positive Activity of Iberdomide Against Heavily Treated MM

Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing

MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients

FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials

Phase 1/2 Trial of Tinostamustine Recruiting Patients with Myeloma, Other Blood Cancers

Pin It on Pinterest